Stock COVANCE INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Covance Inc.

Equities

US2228161004

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Covance Inc.
2014 Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq RE
2014 Covance : LabCorp to pay $6.1 billion for drug trial company Covance RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Covance : LabCorp Completes Acquisition of Covance
PU
Covance : Launches New Solution to Bridge Preclinical to Clinical Development
PR
Covance : Life Sciences Tools and Services Equities Coverage - Agilent Technologies, Thermo Fisher Scientific, Bruker, Quintiles Transnational, and Covance
PR
Covance : Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR
Covance : Ryan & Maniskas, LLP : Announces Investigation of Covance Inc.
PR
Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq
RE
Covance : LabCorp to pay $6.1 billion for drug trial company Covance
RE
Covance : LabCorp to pay $6.1 billion for drug trial company Covance
RE
Covance : LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare Diagnostics Company
BU
Covance : Technical Coverage on Life Sciences Tools and Services Equities - Agilent Technologies, Thermo Fisher Scientific, Pacific Biosciences of California, Sequenom, and Covance
PR
Covance : Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award
PR
Covance : Invites You to Join the Webcast of Its Third Quarter 2014 Financial Results Conference Call
PR
Covance : and Frenova Renal Research Establish
PU
Covance : To Present At The Morgan Stanley Global Healthcare Conference
PR
Covance : Financial Results, Investor Meeting Schedule, Dividend Declaration, and Technical Updates - Research Reports on Quest, Abaxis, Charles River Laboratories, PerkinElmer and Covance
PR
Covance : Invites You to Join the Webcast of Its Second Quarter 2014 Financial Results Conference Call
PR
Covance : Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million
PR
Covance : Increases its Medical and Scientific Leadership with Two Senior-Level Appointments
PU
Covance : C O R R E C T I O N -- Covance Inc./
PU
Covance : New Laws, Pricing of Offering, Recognitions, Donations, and Upcoming Conference Calls - Analyst Notes on Hospira, Prothena, Quintiles, Sirona and Covance
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Covance Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW